• Losmapimod (GW856553X): Workflow Optimization in Inflammatio

  2026-07-14

  Losmapimod (GW856553X) stands out as a dual-action, selective p38 MAPK inhibitor, uniquely enabling precise modulation of inflammation and vascular function in both in vitro and in vivo models. This guide distills actionable protocol enhancements, troubleshooting strategies, and mechanistic insights to help researchers maximize reproducibility and data quality in hypertension and COPD research.

• AMG 487: Precision CXCR3 Antagonist for Macrophage Polarizat

  2026-07-14

  AMG 487 enables targeted and reversible modulation of macrophage polarization through potent CXCR3 inhibition, offering exceptional resolution for dissecting inflammatory versus non-inflammatory signaling. Its robust performance in both cell-based and in vivo models positions it as a pivotal tool for researchers studying chemokine-driven inflammation and acute lung injury.

• Plk1 Regulation of p31comet and Mitotic Checkpoint Disassemb

  2026-07-13

  This study uncovers how Polo-like kinase 1 (Plk1) directly regulates the mitotic checkpoint protein p31comet via phosphorylation, controlling the disassembly of the mitotic checkpoint complex (MCC) and precise cell cycle progression. These findings clarify a critical regulatory mechanism that prevents premature checkpoint inactivation and highlight the complexity of mitotic exit control.

• Structure-Based Discovery of NSP15 Inhibitors for SARS-CoV-2

  2026-07-13

  This study uses structure-based virtual screening to identify thymopentin and oleuropein as potent inhibitors of the SARS-CoV-2 NSP15 endoribonuclease. The findings suggest new avenues for antiviral drug development and highlight the utility of computational screening in targeting viral immune evasion.

• Merbromin Selectively Inhibits SARS-CoV-2 3CLpro: Mechanisti

  2026-07-12

  Chen et al. identified Merbromin as a selective, mixed-type inhibitor of the SARS-CoV-2 main protease 3CLpro through high-throughput screening. This study provides mechanistic clarity for antiviral drug development while highlighting the differential specificity of common proteases in molecular biology workflows.

• Cefotaxime: Third-Generation Cephalosporin in AMR Research

  2026-07-10

  Harnessing Cefotaxime’s robust beta-lactamase resistance, researchers can dissect multidrug resistance and bacterial infection models with unprecedented control. This guide delivers actionable workflows, troubleshooting insights, and direct translation of cutting-edge findings to accelerate next-generation antimicrobial resistance research.

• Dual-Action p38α MAPK Inhibitors Accelerate Dephosphorylatio

  2026-07-09

  The reference study uncovers that specific kinase inhibitors can both block p38α MAPK activity and promote its dephosphorylation by the WIP1 phosphatase. This dual-action mechanism, revealed by structural and biochemical analysis, offers a new strategy for designing more potent and selective tools for inflammation and apoptosis research.

• ISRIB Reverses Inflammation-Driven Accelerated Forgetting in

  2026-07-09

  A recent study demonstrates that ISRIB (trans-isomer), a selective PERK inhibitor, can reverse accelerated forgetting of recognition memory induced by systemic inflammation in mice. These findings highlight the integrated stress response as a mechanistic link between neuroinflammation and pathological memory loss, opening new pathways for targeted intervention in neurodegenerative disease models.

• Optimizing Cancer Assays with Dovitinib (TKI-258, CHIR-258)

  2026-07-08

  This article addresses persistent challenges in cancer cell viability and apoptosis assays by presenting scenario-driven solutions leveraging Dovitinib (TKI-258, CHIR-258), SKU A2168. We discuss evidence-based strategies for protocol optimization, data interpretation, and supplier selection, highlighting how Dovitinib’s multitargeted RTK inhibition and high-quality sourcing from APExBIO enhance reproducibility and research confidence.

• Dovitinib (TKI-258): A Strategic Engine for Translational On

  2026-07-08

  Dovitinib (TKI-258, CHIR-258) exemplifies the next generation of multitargeted receptor tyrosine kinase inhibitors, offering unmatched utility for translational researchers confronting the complexity of RTK-driven cancers. This article explores the mechanistic underpinnings, strategic deployment, and competitive positioning of Dovitinib, blending evidence-backed protocol guidance with insights from cheminformatics and contemporary library design. By bridging rigorous mechanistic rationale with forward-looking translational strategy, we chart a path for researchers to harness Dovitinib’s full potential in both in vitro and in vivo oncology models.

• Cy5 NHS ester(Et): Technical Guidance for Protein Labeling

  2026-07-07

  Cy5 NHS ester(Et) enables efficient, water-soluble fluorescent labeling of amino groups in proteins and biomolecules for applications such as immunofluorescence, flow cytometry, and fluorescence microscopy. It should not be used in ethanol-based protocols or in workflows requiring long-term storage of dye solutions. This guide details best practices for reliable assay setup and troubleshooting.

• Merbromin Selectively Inhibits SARS-CoV-2 3CLpro Protease Ac

  2026-07-07

  Chen et al. identify Merbromin as a potent, selective mixed-type inhibitor of the SARS-CoV-2 main protease (3CLpro), using high-throughput screening of ~6,000 compounds. Their rigorous enzymology shows Merbromin's inhibition is highly specific to 3CLpro and does not affect broad-spectrum serine proteases like Proteinase K, highlighting new avenues for antiviral inhibitor design.

• Lithium-Driven Exosomal Wnt10a Secretion Enhances Osteogenes

  2026-07-06

  This study elucidates how lithium stimulates osteogenesis via Rab11a-mediated exosomal Wnt10a secretion and subsequent activation of Wnt/β-catenin signaling in bone mesenchymal stem cells (BMSCs). These mechanistic insights advance the understanding of bone regeneration and open new avenues for engineering exosome-based therapies and small-molecule interventions in regenerative medicine.

• Troglitazone as a PPARγ Agonist: Expanding Horizons in Tumor

  2026-07-06

  Explore Troglitazone’s distinct role as a PPARγ agonist in modulating the tumor microenvironment and advancing type 2 diabetes research. This article delivers in-depth scientific analysis and actionable insights, setting it apart from existing content.

• Caspase 3/7 Drive Cytoprotective Autophagy in Breast Cancer

  2026-07-05

  Samarasekera et al. uncover that caspase 3 and caspase 7 support autophagy and the DNA damage response during non-lethal stress in human breast cancer cells. This work reveals a conserved, non-apoptotic function for effector caspases in stress adaptation, offering new angles for therapeutic targeting and functional assays.

14687 records 1/980 page Next 12345 下5页 Last page